The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands.
Insulin resistance and non-insulin-dependent diabetes mellitus are major causes of morbidity and mortality in industrialized nations. Despite the alarming rise in the prevalence of this disorder, the initial molecular events that promote insulin resistance remain unclear. The data presented here demonstrate that LG100754, an antidiabetic RXR ligand, defines a novel type of nuclear receptor agonist. Surprisingly, LG100754 has minimal intrinsic transcriptional activity, instead it enhances the potency of proliferator-activated receptor (PPAR) gamma-retinoid X receptor heterodimers for PPARgamma ligands. The ability of LG100754 to both increase PPARgamma sensitivity and relieve insulin resistance implies that a deficiency in endogenous PPARgamma ligands may represent an early step in the development of insulin resistance.
Forman
Barry Marc
BM
City of Hope National Medical Center, Division of Molecular Medicine, The Gonda Diabetes & Genetic Research Center, 1500 East Duarte Road, Duarte, CA 91010, USA. bmforman@earthlink.net
D000818:Animals; D001483:Base Sequence; D015342:DNA Probes; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D008024:Ligands; D051381:Rats; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D012176:Retinoids / Q000494:pharmacology*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*; D014157:Transcription Factors / Q000378:metabolism*
D015342:DNA Probes; D007004:Hypoglycemic Agents; C101596:LG 100754; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D012176:Retinoids; D013764:Tetrahydronaphthalenes; D014157:Transcription Factors